Why is Hem/Onc Pay so Low?

Quote









162k is definitely not the max. Most reps have 15-30+ years in the industry and are well above that. If you’re light in experience I suppose that might be accurate.
 








anonymous said:
Difficulty with reading comprehension? Typical moron.
Click to expand...

Reading comprehension? Check the posting dumbass Why is it in the job description as $125-162? It is a legal requirement in New York to properly disclose salary information and yet Jazz appears to not being doing that. We all know jazz doesn't care about laws. I hope the applicant doesn't get clubbed to death.
 


anonymous said:
Reading comprehension? Check the posting dumbass Why is it in the job description as $125-162? It is a legal requirement in New York to properly disclose salary information and yet Jazz appears to not being doing that. We all know jazz doesn't care about laws. I hope the applicant doesn't get clubbed to death.
Click to expand...
Companies frequently list positions with inaccurate salary info for a variety of reasons dumbass. I’m not saying it’s right. I actually work here and you don’t. The onc salary range listed isn’t even close, which I stated.
 








anonymous said:
How do you know the salaries of reps and managers are different in these BUs? Are you basing this on the inaccurate salary range in the onc job posting?
Click to expand...

I have seen the Onc ranges across roles and came from another BU to EMD. They started higher as a rare disease team for both RSM and NAM roles. Onc doesn’t pay well at Jazz and they are treated as glorified specialty sales slightly higher than PCP.
 


anonymous said:
I have seen the Onc ranges across roles and came from another BU to EMD. They started higher as a rare disease team for both RSM and NAM roles. Onc doesn’t pay well at Jazz and they are treated as glorified specialty sales slightly higher than PCP.
Click to expand...
Interesting. I had heard that as they brought on oncology reps in 2020 that they had to bump up other BU’s bases to be more in line. I will agree that with an increased focus on call metrics that it can have a big pharma feel sometimes.
 













Write your reply...
Top Bottom
Back
Quote